Selivanova G - Search Results

1

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.

Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Strömblad S. Bao W, et al. Among authors: selivanova g. Cell Cycle. 2011 Jan 15;10(2):301-7. doi: 10.4161/cc.10.2.14538. Epub 2011 Jan 15. Cell Cycle. 2011. PMID: 21239882

2

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.

Selivanova G, Iotsova V, Okan I, Fritsche M, Ström M, Groner B, Grafström RC, Wiman KG. Selivanova G, et al. Nat Med. 1997 Jun;3(6):632-8. doi: 10.1038/nm0697-632. Nat Med. 1997. PMID: 9176489

3

Reactivation of mutant p53: a new strategy for cancer therapy.

Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Selivanova G, et al. Semin Cancer Biol. 1998;8(5):369-78. doi: 10.1006/scbi.1998.0099. Semin Cancer Biol. 1998. PMID: 10101802 Review.

4

Inactivation of Myc-induced p53-dependent apoptosis in human tumors.

Henriksson M, Selivanova G, Lindström M, Wiman KG. Henriksson M, et al. Among authors: selivanova g. Apoptosis. 2001 Feb-Apr;6(1-2):133-7. doi: 10.1023/a:1009644716727. Apoptosis. 2001. PMID: 11321036 Review.

5

Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.

Heessen S, Leonchiks A, Issaeva N, Sharipo A, Selivanova G, Masucci MG, Dantuma NP. Heessen S, et al. Among authors: selivanova g. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1532-7. doi: 10.1073/pnas.022306499. Epub 2002 Jan 22. Proc Natl Acad Sci U S A. 2002. PMID: 11805282 Free PMC article.

6

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Bykov VJ, et al. Among authors: selivanova g. Nat Med. 2002 Mar;8(3):282-8. doi: 10.1038/nm0302-282. Nat Med. 2002. PMID: 11875500

7

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Bykov VJ, et al. Among authors: selivanova g. Carcinogenesis. 2002 Dec;23(12):2011-8. doi: 10.1093/carcin/23.12.2011. Carcinogenesis. 2002. PMID: 12507923

8

Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain.

Protopopova M, Selivanova G. Protopopova M, et al. Among authors: selivanova g. Cell Cycle. 2003 Nov-Dec;2(6):592-5. Cell Cycle. 2003. PMID: 14504475

9

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. Issaeva N, et al. Among authors: selivanova g. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13303-7. doi: 10.1073/pnas.1835733100. Epub 2003 Oct 31. Proc Natl Acad Sci U S A. 2003. PMID: 14595027 Free PMC article.

10

p53: fighting cancer.

Selivanova G. Selivanova G. Curr Cancer Drug Targets. 2004 Aug;4(5):385-402. doi: 10.2174/1568009043332934. Curr Cancer Drug Targets. 2004. PMID: 15320716 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters